Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
ASX data centre share forecasts AI fuelled earnings surge
AI and cloud demand underpin bullish growth outlook
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.00 | 22.50 | 0.24% |
| CAC 40 | 8,334.50 | 66.68 | -0.79% |
| DAX 40 | 26,258.11 | 311.88 | -1.17% |
| Dow JONES (US) | 53,185.90 | 374.09 | -0.70% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,291.35 | 275.64 | -1.08% |
| NASDAQ | 26,370.89 | 31.54 | -0.12% |
| Nikkei 225 | 66,155.86 | 156.07 | -0.24% |
| NZX 50 Index | 13,809.51 | 107.79 | -0.77% |
| S&P 500 | 7,686.14 | 25.62 | -0.33% |
| S&P/ASX 200 | 9,051.60 | 26.60 | 0.29% |
| SSE Composite Index | 3,985.75 | 0.55 | -0.01% |